Updating results

5 results for ibrance

Sort: Relevance | Date

Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA495)

Evidence-based recommendations on palbociclib (Ibrance) as initial endocrine-based therapy for hormone receptor-positive, HER2-negative, locally advanced or

Technology appraisal guidance Published December 2017

Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA619)

Evidence-based recommendations on palbociclib (Ibrance) with fulvestrant for hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer

Technology appraisal guidance Published January 2020

Breast cancer patients to have further NICE-approved drug combination option on Cancer Drugs Fund

Another potentially life-extending drug combination for some people with advanced breast cancer will now be available on the Cancer Drugs Fund (CDF) following its approval by NICE in final guidance published today (15 January 2020).

News Published January 2020 Last updated January 2020

Breast cancer patients to have routine access to two life extending drugs after new deal, say NICE in draft guidance

NICE has recommended palbociclib and ribociclib for routine funding after the companies lowered the prices and gave more evidence for their effectiveness.

News Published November 2017 Last updated November 2017

Breast cancer drug costs too high in relation to benefits for routine NHS funding

NICE does not recommend breast cancer drug palbociclib (Ibrance, Pfizer) because its cost is too high in relation to its potential benefits in draft guidance out for consultation.

News Published February 2017 Last updated February 2017